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Abstract
Background: Coeliac disease (CD) is a autoimmune disease characterised by mucosal inflammation in the small
intestine in response to dietary gluten. Genetic factors play a key role with CD individuals carrying either the HLA-
DQ2 or HLA-DQ8 haplotype, however these haplotypes are present in half the general population making them
necessary but insufficient to cause CD. Epigenetic modifications, including DNA methylation that can change in
response to environmental exposure could help to explain how interactions between genes and environmental
factors combine to trigger disease development. Identifying changes in DNA methylation profiles in individuals
with CD could help discover novel genomic regions involved in the onset and development of CD.
Methods: The Illumina InfiniumMethylation450 Beadchip array (HM450) was used to compare DNA methylation
profiles in saliva, in CD and non-CD affected individuals. CD individuals who had been diagnosed at least 2 years
previously; were on a GFD; and who were currently asymptomatic; were compared to age and sex-matched non-
CD affected healthy controls. Bisulphite pyrosequencing was used to validate regions found to be differentially
methylated. These regions were also validated in a second larger cohort of CD and non-CD affected individuals.
Results: Methylation differences within the HLA region at HLA-DQB1 were identified on HM450 but could not be
confirmed with pyrosequencing. Significant methylation differences near the SLC17A3 gene were confirmed on
pyrosequencing in the initial pilot cohort. Interestingly pyrosequencing sequencing of these same sites within a
second cohort of CD and non-CD affected controls produced significant methylation differences in the opposite
direction.
Conclusion: Altered DNA methylation profiles appear to be present in saliva in CD individuals. Further work to
confirm whether these differences are truly associated with CD is needed.
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Background
Coeliac disease (CD) is a chronic autoimmune disease
characterised by mucosal inflammation in the small in-
testine in response to dietary gluten, in genetically sus-
ceptible individuals [1], with the only treatment being a
life-long gluten free diet (GFD). It is highly prevalent, af-
fecting approximately 1% of the population worldwide
[2]. Clinical presentations can differ between individuals,
making it challenging for clinicians to recognise [3]. To
complicate matters further, accurate serology and intes-
tinal histopathology for screening and diagnosis, requires
active consumption of gluten which can be problematic
given the popularity of a GFD, whilst the invasive nature
of a gastroscopy carries its own risks.
Genetic factors play a key role as individuals with a
family history of CD have a significantly higher likeli-
hood of also developing disease [4]. Individuals with CD
carry either the HLA-DQ2 or HLA-DQ8 haplotype. The
HLA-DQ2 haplotype is found in 90–95% of patients
with CD [5], while the HLA-DQ8 haplotype is present in
approximately 5% of patients [6]. These haplotypes are
present in up to 56% of the general population making
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them necessary but not sufficient for the development of
CD [7]. Environmental factors including age at first
exposure to gluten, antibiotic and proton pump inhibitor
use, and surgeries and trauma have also been associated
with CD [8–12]. However, the exact mechanism of how
these factors contribute to the development of CD is
currently unknown.
Gene-environment interactions are mediated by epigen-
etic modifications of the genome, and changes to epigen-
etic profiles can occur in response to changes in the
environment [13]. DNA methylation is a type of epigen-
etic modification that may partially explain how interac-
tions between genes and environmental factors combine
to trigger disease development. Altered DNA methylation
profiles have been observed in gastrointestinal inflamma-
tory disorders, including CD, autoimmune conditions and
cancer [14–16]. The identification of DNA methylation
profiles that are associated with disease state, offers the
potential for discovering new pathways integral to the
disease process. DNA methylation profiles associated with
disease state are also potential disease biomarkers with
utility in disease screening.
DNA methylation profiles unique to CD irrespective
of whether individuals are consuming gluten could be a
valuable screening tool, particularly if the DNA methyla-
tion markers were present in easily an accessible tissue
like saliva. Altered DNA methylation profiles have been
reported in individuals with CD that were independent
of gluten consumption [14]. However, these differences
were observed in intestinal mucosal tissue, which require
a gastroscopy to obtain tissue. It is unknown whether
the differences in DNA methylation profiles are unique
to intestinal mucosal tissue or are also present in other
tissues. We have previously shown that DNA methyla-
tion profiles in saliva correlated well with DNA methyla-
tion profiles from intestinal mucosal tissue [17]. The
current study compared DNA methylation profiles in
saliva from individuals with and without CD, to identify
DNA methylation profiles unique to GFD managed CD.
Methods
Participant recruitment, selection criteria and data
collection
Recruitment was carried out between April 2014 and
August 2017. Individuals were recruited at the annual
Gluten-Free Expos in Sydney and Melbourne, Australia.
Following written informed consent, individuals were
asked questions regarding their socio-demographic char-
acteristics, health and disease status, as previously de-
scribed [18] (Additional file 1). Saliva samples were
collected from all participants using the Oragene DNA
OG500 self-collection kits (DNA Genotek, Canada). The
study was approved by the Western Sydney University
Research Ethics Committee (approval number H10513)
and the Macquarie University Human Ethics Committee
(approval number 5201700199) and was carried out in
accordance with the ethical standards laid down in the
1964 Declaration of Helsinki and its later amendments.
Pilot cohort: Illumina Infinium HumanMethylation450
Beadchip (HM450) array
The pilot cohort consisted of n = 59 individuals consist-
ing of CD individuals and non-affected controls. CD
status was confirmed via endoscopy reports. For inclu-
sion, these individuals had a CD diagnosis that was more
than 2 years old, adhered to a strict gluten free diet since
diagnosis; were free of any associated symptoms; and
carried at least one HLA-DQ2 or DQ8 haplotype. For
non-affected controls, these individuals reported no fam-
ily history of CD, and were age (± 3 years) and sex
matched to the CD group. Non-affected controls were
free of any associated symptoms; carried at least one
HLA-DQ2 or DQ8 haplotype and were negative for CD
using the Simtomax® CD assay, a point-of-care test that
detects antibodies against deamidated gliadin peptides
(HealthScreen Solutions, AUS). This is a commercially
available screening tool that has a negative predictive
value of 99.1% [19].
Secondary cohort: validation group to confirm any
methylation differences
An additional n = 221 CD cases and non-affected con-
trols were recruited to enable validation of any differen-
tially methylated CpG sites identified in the pilot cohort.
These individuals were defined as having CD if they ful-
filled the following criteria: had been diagnosed with CD
via duodenal biopsy by a gastrointestinal specialist; were
currently on a gluten free diet; and carried at least one
HLA-DQ2 or HLA-DQ8 haplotype. Individuals were
classified as non-affected controls if they reported not
having CD or CD associated symptoms and were not on
a gluten-free diet (GFD). For all individuals, body mass
index (BMI) was analysed as a categorical variable accord-
ing to World Health Organization guidelines [20]. Alcohol
consumption was categorised into zero, 1–2, and 3–7
standard drinks per week. Smoking status was dichoto-
mised into never smoked and having ever smoked. Partici-
pants reported if they had ever been clinically diagnosed
with cancer, asthma, or any of the following autoimmune
conditions: Type 1 diabetes mellitus; Autoimmune thyroid
disease; Rheumatoid arthritis; Lupus; Addison’s disease;
Dermatitis herpetiformis; Alopecia, Autoimmune Hepa-
titis, Multiple Sclerosis, Sjogren’s syndrome or Psoriasis.
Data from each autoimmune condition variable was com-
bined to generate the variable ‘other autoimmune condi-
tions’ as the prevalence of each individual condition was
low. Individuals with missing data; who were current
smokers; or reported a history of cancer were excluded.
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DNA extraction and HLA genotyping
Whole saliva was collected from all participants. Saliva
(2 ml) was collected using the Oragene DNA OG500
self-collection kits (DNA Genotek, Canada). Genomic
DNA was extracted as per the Oragene prep-IT L2P
(DNA Genotek, Canada) protocol, and purified using the
Qiagen DNA mini kit (Qiagen, Germany) and samples
were stored at − 20 °C until analysis. All samples were ge-
notyped for the CD susceptibility haplotypes HLA-DQ2
and HLA-DQ8 using TaqMan SNP genotyping assays
(Life Technologies, AUS): C_11409965_10, C_29315313_
10, C_58662585_10, C_29817179_10, and a custom de-
signed assay for rs4713586, as previously described [21].
Illumina Infinium HumanMethylation450 BeadChip
analysis
Genomic DNA (500 ng) was treated with sodium bisul-
phite using the EZ DNA methylation kit (Zymo Re-
search, CA, USA), as per the manufacturers protocol.
Bisulphite converted genomic DNA was hybridized to
the Illumina Infinium HumanMethylation450 BeadChip
(Illumina, San Diego, CA), using the Illumina supplied
reagents. Samples were randomly allocated across array
chips (mix of CD and control samples on each array).
Amplification, hybridization, washing, labelling and
scanning of the array was performed by the Australian
Genome Research Facility (AGRF) a commercial fee for
service provider. Illumina’s GenomeStudio v2011.1 with
Methylation module 1.9.0 software, with the default Illu-
mina settings and the Illumina HumanMethylation450
15,017,482 v.1.2 manifest file, was used in the generation
of data. Raw IDAT files containing signal intensities for
each probe were extracted using Illumina GenomeStudio
software and imported into RStudio using the methylumi
and minfi packages. Data from samples passing initial
quality filtering have been deposited into the Gene Ex-
pression Ominibus (GSE119078). Multi-dimensional
scaling (MDS) plots of variably methylated probes on
the sex chromosomes were used to confirm that the pre-
dicted sex matches the reported sex for each participant.
Data quality control and processing steps were con-
ducted using the methylumi and wateRmelon packages
[22]. The pfilter function was used to discard samples
with a detection p-value > 0.01 in at least 1% samples
and/or a bead count less than 3 in 5% of samples. Data
was normalised using the dasen function [22]. Probes
targeting sites on sex chromosomes, non-CpG targeting
probes, those that containing a SNP with minor allele
frequency > 1% within 5 bp of the single base extension
site [23], and cross hybridising probes [24] were re-
moved from all analyses.
Saliva contains a mixture of different cell types, and
cell-type proportions may differ across individuals. Sur-
rogate variable analysis using the sva package was used
to identify potential sources of variation, including cell
type heterogeneity within samples and potential batch
effects [25] [26]. sva using the “leek” method identified 3
surrogate variables that were then adjusted for in subse-
quent analysis.
Analyses were performed to test differences in DNA
methylation between individuals with CD and healthy con-
trols at the individual probe level. To model the effect of
sample-specific variables, linear regression for each probe
using age, sex and CD status as independent variables were
performed using the limma package [27]. Prior to analysis,
the log2 ratio of β-values was calculated and denoted as
M-values which were used for statistical analyses, while β-
values were used for interpretation of the results. P-values
were adjusted for multiple testing according to the false
discovery rate (FDR) procedure of Benjamini Hochberg.
Significantly differentially methylated probes (DMPs)
were selected using a cut-off of a |β| difference of ≥5%
and an adjusted p < 0.05. The DMRcate package [28]
was then used to identify significantly differentially
methylated regions (DMRs) (p < 0.05, minimum cpg
sites = 2) between CD and healthy control samples, as
previously described [29].
Gene ontology
Functional annotation analysis and gene ontology (GO)
enrichment analysis was performed using the missMethyl
package [30]. The gometh function (prior.prob. = TRUE)
was used to test GO enrichment for significant CpGs. In
addition, the gometh function was used to perform path-
way enrichment analysis based on the Kyoto Encyclopedia
of Genes and Genomes (KEGG) classification databases to
identify significant pathways. Following this, the topGO or
topKEGG function of the limma package was used to
identify the most significant GO terms and KEGG path-
ways. In addition, Database for Annotation, Visualization
and Integrated Discovery (DAVID version 6.8) Bio-
informatics Resources web-based software tool was
used to perform functional annotation analysis and GO
enrichment analysis. Gene identifiers were uploaded,
and functional annotation analysis was performed,
against the human reference genome (GRCh37/hg19)
using a Benjamini-Hochberg multiple-test adjustment
threshold of p < 0.05. Pathway enrichment analysis
based on the protein annotation through evolutionary
relationship and KEGG classification databases was
used to identify significant pathways.
Sanger sequencing and Bisulphite pyrosequencing
CpG sites within genes that mapped to DMRs with a
mean |Δβ| > 5% were further investigated. The UCSC
genome browser was used to investigate whether known
DNA variants were present in and around the CpG sites
of interest. In cases where known DNA variants (single
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nucleotide polymorphisms SNPs) were reported that
may alter the CpG site, and thus methylation status,
DNA sequencing was used to determine whether under-
lying DNA variation was responsible for differences in
methylation. All sequencing assays were performed by
AGRF (Additional file 2: Table S1). Samples from across
the methylation profile (high vs low) were sequenced.
Forward and reverse sequences were provided to us by
AGRF, and sequences were analysed using Sequencer
v.5.4 (Genecodes,USA).
In the pilot cohort, pyrosequencing assays were per-
formed on 6 CpG sites within the HLADQB1 (1 CpG),
SLC17A3 (3 CpG) and ZFYVE19 (2 CpG) genes to con-
firm the methylation status of these CpG sites. These sites
were selected as they did not contain underlying DNA
variations, had |Δβ| > 5% at the CpG site; and primers to
enable accurate amplification for pyrosequencing could be
designed (Additional file 2: Table S2). All pyrosequencing
assays were designed, optimised, performed, and analysed
by AGRF (Additional file 2). Percentage methylation at
the select CpG sites for each sample were provided to us
by AGRF. CpG sites that were confirmed as being differ-
entially methylated in the pilot cohort, were then quanti-
fied in the second larger validation cohort using the same
pyrosequencing assays.
Statistical analysis
For description of participant’s demographic and clinical
characteristics, mean and standard deviation (SD) were
used for continuous variables with normal distribution,
and proportions were used for categorical variables. A
logistic regression model was applied to the demo-
graphic parameters with CD status, adjusted for age and
sex. Independent T- tests were used to compare DNA
methylation levels between CD cases and non-affected
controls for sites measured via pyrosequencing.
Results
The pilot cohort comprised of saliva samples obtained
from 31 CD individuals (12 male) and 28 controls (13
male), matched for sex and age. The mean age of indi-
viduals with CD was 42 ± 15 years old and healthy con-
trols was 37 ± 14 years old. For CD individuals, a family
history of CD was reported in 39% of the group, and the
mean length of time since diagnosis was 8.7 ± 6.5 years
and ranged from 2.1 to 26.2 years. All individuals were
Caucasian and no significant differences in BMI, smok-
ing status, and alcohol consumption between the two
groups was observed. The frequency of another auto-
immune condition was higher in individuals with CD
compared to controls (45.2% vs 17.9%). Demographic in-
formation is summarised in Table 1.
DNA methylation was quantified using the Illumina
Infinium HumanMethylation450 Beadchip (HM450).
Following quality control, pre-processing and normalisa-
tion, all 31 CD and 28 control samples were used for ana-
lysis. A total of 20 differentially methylated positions
(DMPs) were identified (adj. p value < 0.05), 9 hyper-
methylated and 11 hypomethylated, between CD and con-
trols, after adjusting for age, sex and are shown in Table 2.
Region analysis of DNA methylation across adjacent
probes did not identify any regions that were differentially
methylated using a Bonferroni adjusted p-value < 0.05.
Using the criteria of an unadjusted p < 0.05 and mean
|Δβ| ≥ 5%, 351 regions 147 hypermethylated and 204
hypomethylated, that mapped to 334 unique annotated
genes were identified. The top regions are summarised in
Table 3. Functional annotation analysis of genes that
mapped to these regions did not identify any terms that
were significantly enriched (Bonferroni adj. p value <
0.05), however the top 10 terms identified by DAVID in-
cluded Type 1 diabetes mellitus (non-adjusted p = 0.02),
autoimmune thyroid disease (non-adjusted p = 0.04) and
rheumatoid arthritis (non-adjusted p = 0.03).
CpG sites within the SET and MYND domain contain-
ing 3 (SMYD3) gene, the solute carrier family 17 member
3 (SLC17A3) gene, the zinc finger FYVE-type containing
19 (ZFYVE19) gene, the major histocompatibility
Table 1 Characteristics of the pilot cohort
Variable Coeliac
(n = 31)
Control
(n = 28)
p value
Age (mean ± SD years) 42 ± 15 37 ± 14 0.64
Sex 0.57
Male 12 (38.7%) 13 (46.4%)
Female 19 (61.3%) 15 (53.6%)
BMI (kg/m2) 0.78
18.5–24.99 14 (45.2%) 15 (53.6%)
25–29.99 11 (35.5%) 9 (32.1%)
> 30 6 (19.4%) 4 (14.3%)
Standard drinks per week 0.07
Zero 17 (54.8%) 6 (21.4%)
1–2 5 (16.1%) 5 (17.9%)
3–7 5 (16.1%) 9 (32.1%)
8 or more 4 (12.9%) 8 (28.6%)
Smoking status 0.19
Quit 8 (25.8%) 10 (35.7%)
Never smoked 23 (74.2%) 18 (64.3%)
Asthma 0.43
Yes 10 (32.3%) 10 (35.7%)
No 21 (67.7%) 18 (64.3%)
Other Autoimmune Condition 0.01
Yes 14 (45.2%) 5 (17.9%)
No 17 (54.8%) 23 (82.1%)
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complex, class II, DP beta 1 (HLADPB1) gene and the
major histocompatibility complex class II DQ beta I
(HLADQB1) were selected for further investigation based
on the magnitude of mean DNA methylation difference
across all CpG sites within the region (Fig. 1).
Underlying DNA variants can cause disruption of
methylation at CpG sites resulting in bi or tri modal
methylation patterns (~ 0%, ~ 50% and ~ 100%). The tri
modal pattern of DNA methylation observed at the
cg04798314 (SYMD3) and cg14373797 (HLA-DPB1)
sites (Fig. 2) is indicative of underlying DNA variants
disrupting the CpG site. Known DNA polymorphisms at
these sites were identified using the UCSC genome
browser. The rs201044038 polymorphism in SMYD3 re-
sults in the insertion of a thymine (T) between the cyto-
sine and guanine leading to the loss of the cg4798314 site
and subsequent methylation. The population frequency of
rs201044038 is unknown and was not excluded during the
initial methylation pre-processing when probes within
known variants with a minor allele frequency greater than
1% were removed. Similarly, the rs9276 variant in
HLADPB1 results in a substitution of a guanine leading to
a loss of the cg14373797 site and loss of methylation. No
Table 2 Differentially methylation positions identified between individuals with CD and non-affected controls
hg19 coordinates Probe Associated Gene Genomic Position Adj. P Value Δβ
Hypomethylated
chr19:14142585 cg06860352 IL27RA 5’UTR p < 0.05 −0.01
chr8:2060933 cg05570806 MYOM2 Body p < 0.05 − 0.01
chr8:128748337 cg03076047 MYC 5’UTR p < 0.05 − 0.02
chr7:97923044 cg27013914 BAIAP2L1 Body p < 0.05 −0.02
chr2:11864427 cg15380473 p < 0.05 −0.02
chr19:649301 cg18811158 RNF126 Body p < 0.05 −0.02
chr17:45907760 cg12380854 LRRC46;MRPL10 TSS1500 p < 0.05 −0.02
chr10:135141628 cg11126081 CALY Body p < 0.05 −0.03
chr11:33334443 cg26400421 HIPK3 Body p < 0.05 −0.03
chr5:156516798 cg19063654 HAVCR2 Body p < 0.05 −0.04
chr16:6976709 cg16716449 A2BP1 5’UTR p < 0.05 −0.10
Hypermethylated
chr12:30251537 cg09151187 p < 0.05 0.03
chr14:68283333 cg12952552 ZFYVE26 TSS1500 p < 0.05 0.01
chr17:61920550 cg04367190 SMARCD2 TSS1500 p < 0.05 0.01
chr6:7389895 cg05371005 CAGE1;RIOK1 5’UTR p < 0.05 0.01
chr6:26027625 cg12474759 HIST1H4B TSS1500 p < 0.05 0.01
chr3:112738652 cg05582165 C3orf17 TSS1500 p < 0.05 0.01
chr11:14542136 cg12352359 PSMA1 TSS1500 p < 0.05 0.01
chr10:81741832 cg18762849 p < 0.05 0.01
chr13:52586133 cg18796523 ALG11;ATP7B TSS1500 p < 0.05 0.01
TSS = 200–1500 bases upstream of transcription start site, 5’UTR = 5′ – untranslated region upstream from initiation codon, Body = body of gene.
Positive Δβ values indicate hypermethylation in individuals with CD; negative Δβ values indicate hypomethylation in individuals with CD
Table 3 Top differentially methylated regions (DMRs)
identified between CD individuals and non-affected controls
(|Δβ| > 5%, p < 0.05)
hg19 Coordinates No. of Probes Associated Gene Δβ
Hypomethylated
chr6:33053576–33,054,001 5 HLA-DPB1 −0.08
chr2:113190072–113,190,197 2 RGPD8 −0.07
chr2:130794753–130,795,678 4 FAR2P1 −0.06
chr20:623089–623,421 4 SRXN1 −0.06
chr7:100343083–100,343,110 2 ZAN −0.05
chr6:31275148–31,276,797 24 HLA-B −0.05
chr15:29034942–29,034,950 2 PDCD6IPP2 −0.05
Hypermethylated
chr1:246667857–246,668,601 2 SMYD3 0.13
chr17:6557720–6,558,815 6 MIR4520–2 0.09
chr15:41098188–41,100,308 14 ZFYVE19 0.07
chr6:32632694–32,633,163 8 HLA-DQB1 0.06
chr6:25882328–25,882,590 5 SLC17A3 0.05
chr11:288301–288,305 2 ATHL1 0.05
chr5:77146796–77,147,141 3 TBCA 0.05
chr14:24779400–24,780,926 14 LTB4R2 0.05
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Fig. 1 Differentially methylated regions (DMRs) of interest between CD and controls on HM450 array. β values (mean ± SE) from the HM450 array
at each probe site are presented. CpG sites with the boxes were investigated by pyrosequencing
Fig. 2 Differentially methylated CpG sites within the DMR on HM450 array analysis between CD and controls
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DNA variants were reported at the CpG sites within
HLADQB1, SLC17A3 and ZFYVE19.
DNA sanger sequencing to genotype the rs201044038
and rs9276 polymorphisms within the pilot cohort found
the frequency of rs201044038 was significantly lower in
CD individuals when compared to non-affected controls
(57% vs 96%, p = 0.002), while the frequency of rs9276
was significantly higher in CD individuals when compared
to non-affected controls (52% vs 4%, p < 0.001). Individ-
uals who were heterozygous or homozygous for the
rs246668601 or the rs9276 variants had reduced or no
methylation at these sites.
Bisulphite pyrosequencing was used to validate 6 CpG
sites within the HLADQB1, SLC17A3 and ZFYVE19
genes within the pilot cohort. Three sites near the
SLC17A3 gene were confirmed as being differentially
methylated between CD and control individuals (Fig. 3a).
Pyrosequencing did not confirm methylation differences
for the two sites within ZFYVE19 gene, cg13045913
(6.7% vs 4.9%, p = 0.17) and cg25498107 (20.3% vs
16.3%, p = 0.21). The cg10982913 in HLADQB1 could
not be validated due to the large number of polymor-
phisms within the region.
We subsequently recruited an additional n = 202 indi-
viduals, 139 CD and 63 controls to determine whether
the methylation differences near SLC17A3 could be rep-
licated in a larger dataset (validation cohort). Within the
validation cohort, the mean age of individuals with CD
was 44.8 ± 15 years old and healthy controls was 40.5 ±
15 years old. There were significantly more females in
the CD group (p < 0.001) and a higher proportion of CD
individuals reported having been diagnosed with another
autoimmune condition. No significant difference in age,
BMI, family history of CD, or lifestyle factors was
observed between CD and nob-affected controls in this
cohort (Table 4).
Pyrosequencing of the three cg sites near the SLC17A3
region in the validation cohort (n = 202) found signifi-
cant differences in methylation between CD and controls
(Fig. 3b). Interestingly, the direction of the methylation
differences between the groups was in the opposite dir-
ection to that seen in the initial cohort, with methylation
at all three sites lower in CD compared with controls in
the larger cohort.
Genotyping of the SYMD3 variant rs201044038 in the
validation cohort found no difference in the frequency
between the CD and unaffected controls (71.4% vs
76.7%, p = 0.40). While the frequency of the rs9276 vari-
ant in the HLADPB1 gene was found to be higher in the
CD group (33.1% vs 16.4%, p = 0.006).
Discussion
CD is a chronic autoimmune condition that can be chal-
lenging to recognise and diagnose. It has a known gen-
etic component with CD individuals carrying either the
HLA-DQ2 or HLA-DQ8 haplotype. However, these
Fig. 3 Differentially methylated CpG sites validated by pyrosequencing. a: Initial cohort. b: Validation cohort
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haplotypes are present in up to 56% of the general popu-
lation making them necessary but not sufficient for the
development of CD [7]. Environmental factors have been
reported to play a role in triggering CD in genetically
susceptible individuals however the exact mechanism of
how they contribute to disease development is unknown.
Changes in DNA methylation may help to explain how
environmental triggers can induce disease development.
To our knowledge this is the first study to investigate
DNA methylation in oral mucosa cells from saliva in in-
dividuals with managed CD and healthy controls. Our
preliminary findings identified DNA methylation differ-
ences in the HLA region near the SLC17A3 gene.
Altered DNA methylation profiles in CD have been
previously reported. That study compared DNA methy-
lation profiles from intestinal mucosal biopsy samples in
individuals with active and GFD treated CD, with non-
CD individuals [14]. They analysed the duodenal mucosa
by separating the epithelial and immune cell populations
of the biopsy samples and found a cell-type specific
methylation signature with the epithelial methylome
being characterised by the loss of CpG island boundaries
and altered gene expression. DMPs were found at 43
sites in the epithelial fraction and 310 sites in immune
fraction, of which genes within the HLA region were dif-
ferentially methylated in both cell populations [14].
Methylation differences within and around the HLA
region were also identified on array in our study
(Table 3). Methylation differences within HLA-DQB1
and HLADPB were observed. The polymorphic nature
of the HLA region prohibited validation of the sites
within HLADQB1, while the methylation difference at
HLADPB was the result of an underlying genetic vari-
ant. The rs9276 variant (within HLADPB) disrupts the
cg14373797 site causing a loss in methylation. Site-
specific methylation changes due to underlying gen-
etic variation was observed in the Fernandez-Jimenez
study [14], and has also been reported in inflamma-
tory bowel disease [31]. Fernandez-Jimenez et al. sug-
gested that the 13 CD associated SNPs which
correlated with the methylation level of a single CpG
site in the gene body of MMEL1 were methylation
quantitative trait loci (mQTL).
Methylation differences at three CpG sites upstream of
the SLC17A3 gene were also observed in CD individuals
compared to non-affected healthy controls in the pilot
cohort. SLC17A3 forms part of the extended HLA region
and encodes a voltage-driven transporter protein that is
involved in the urate elimination. Elevated uric acid
levels are markers of oxidative stress and inflammation,
where uric acid, an antioxidant is produced in response
to inflammation and oxidative stress [32]. Individuals
with CD have elevated uric acid serum levels when com-
pared to healthy controls which may reflect the inflam-
mation and oxidative stress that is characteristic of CD
even when following a GFD [33]. Interestingly, the direc-
tion of methylation differences between the pilot and
validation cohort were in opposite directions. Hyperme-
thylation in CD individuals compared to healthy controls
in the pilot cohort, while hypomethylation in CD indi-
viduals in the secondary cohort, at all three sites was
seen. The location of the sites would suggest that alter-
ations in methylation could affect chromatin interactions
and/or transcription factor binding and influence the ex-
pression of SLC17A3 or downstream genes. Loss of
function mutations in SLC17A3 have been shown to re-
sult in hyperuricemia [34] therefore, hypermethylation at
these regions may result in elevated blood uric acid
levels, which is consistent with elevated levels of uric
acid levels seen in individuals with CD [32]. Further test-
ing in another cohort could help to elucidate whether
methylation differences at these sites are present and the
direction of the methylation difference. Following con-
firmation of the direction of methylation change, tran-
scriptome analysis would help to determine whether
Table 4 Demographic characteristics of the validation cohort
Variable Coeliac
(n = 139)
Control
(n = 63)
p value
Age (mean ± SD years) 44 ± 15 40 ± 15 0.06
Sex 0.001
Male 16 (11.5%) 22 (34.9%)
Female 123 (88.5%) 41 (65.1%)
BMI (kg/m2) 0.53
18.5–24.99 67 (49.3%) 31 (49.2%)
25–29.99 38 (27.9%) 21 (33.3%)
> 30 31 (22.8%) 11 (17.5%)
Standard drinks per week 0.50
Zero 67 (48.2%) 29 (46.0%)
1–2 35 (25.2%) 13 (20.6%)
3–7 21 (15.1%) 15 (23.8%)
8 or more 16 (11.5%) 6 (9.5%)
Smoking status 0.12
Quit 15 (10.8%) 12 (19.0%)
Never smoked 124 (89.2%) 51 (81.0%)
Family history of CD 0.10
Yes 70 (50.7%) 24 (38.1%)
No 68 (49.3%) 39 (61.9%)
Asthma 0.28
Yes 31 (22.3%) 10 (15.9%)
No 108 (77.7%) 53 (84.1%)
Other Autoimmune Condition 0.04
Yes 54 (38.8%) 12 (19.0%)
No 85 (61.2%) 51 (81.0%)
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these methylation differences induce expression changes
in SLC17A3 or surrounding genes.
The distribution pattern of methylation seen at
cg12310025 site near SLC17A3 (Fig. 3b) is not repre-
sentative of underlying DNA patterns. Instead the tri
modal pattern may be a result of cell-type specific
methylation differences, environmental exposures or
age-related [35]. Interestingly, the distribution pattern
is similar for both individuals with CD and healthy
controls indicating that the patterns observed could be a
result of the proportion of methylated and unmethylated
cells in a sample. Saliva samples contain a heterogeneous
collection of cells and thus the proportion of cell types in
an individual’s sample could result in the differing methy-
lation patterns observed. In addition, differences in envir-
onmental exposures between our participants may have
led to small to moderate differences in DNA methylation
variation. DNA methylation has been shown to be corre-
lated with chronological age resulting in bi and tri modal
patterns of methylation, and 23% of variation in DNA
methylation can be attributed to chronological age [36].
The opposing direction of methylation differences near
SLC17A3 between our two cohorts highlights the im-
portance of validating findings, as well as the limitations
of using smaller sample sizes. The differing results ob-
served indicates that the smaller pilot cohort was not re-
flective of the larger validation cohort, or vice versa. In
the pilot cohort recruitment of CD and non-affected
controls were similar, whereas the validation cohort had
a higher proportion of CD (69%) compared to controls
(31%). Furthermore, individuals with a family history of
CD are at a ten times higher risk of developing CD. The
exclusion criteria for non-affected controls in the pilot
cohort included a family history of disease. Whereas in
the validation cohort, 38.4% of non-affected controls re-
ported a family history of CD. This may have impacted
on the results and led to the discrepancies observed.
Limitations of the study include use of self-reported
data which can be subject to recall bias. Self-reporting of
CD status may have led to false-positive CD classifica-
tion. However, the CD cohort was restricted to individ-
uals who had been diagnosed via an intestinal biopsy by
a gastrointestinal specialist. Endoscopy reports for a sub-
set of CD participants, were also obtained to verify the
diagnosis to minimise the chance of misclassification.
While the healthy control individuals within the pilot
cohort were negative for CD serology and associated
symptoms at recruitment, they carry the HLADQ2 or
HLADQ8 susceptibility haplotypes and may develop CD
in later life. In the validation cohort, false negative CD
classification for controls is also possible given the high
prevalence of CD (1 in 70) in the general population and
that individuals with CD can be asymptomatic. The
disproportionate number of female participants in the
validation cohort is another factor. While CD is more
frequent in females to males (1.33 to 1) this does not ac-
count for the 75% of female participants in the validation
cohort. Recruitment setting may account for this as most
attendees at the Gluten Free Expos were female due to
the events being marketed as food and cooking demon-
strations. Recruitment in a more gender neutral setting
could help to correct this imbalance. However, as no dif-
ferences in age at diagnosis, presenting symptoms or re-
sponse to treatment has been reported between males
and females with CD [37], it is unlikely sex impacted the
results.
Perhaps the largest factor that may have contributed
to the difference in results between the Fernandez-
Jimenez [14] and our study was the different tissues
used, duodenal mucosal tissue vs saliva. Saliva, like intes-
tinal mucosa contains a mixture of different cell types,
including epithelial and immune cells. To account for
cell heterogeneity, surrogate variable analysis was used
to identify and adjust for this variation within samples,
however given the cell type specific methylation profiles
seen in duodenal tissue, it is possible that the differences
in the mixture of cell populations in whole saliva com-
pared with the epithelial and immune duodenal frac-
tions, may have also contributed to the lack of large
methylation differences between CD and health controls.
Another factor that may have contributed to the ab-
sence of any large DNA methylation differences, was
that all our CD individuals had been diagnosed at least
2 years prior, were on a strict gluten free diet, and re-
ported being symptom free. Our rationale for using CD
individuals without active disease was to identify DNA
methylation markers that were unique to CD regardless
of disease state. We had hypothesised that any DNA
methylation changes that occurred in the development
of CD would be permanently maintained given that a
CD diagnosis is lifelong. The presence of a CD epigen-
etic signature in both active and GFD-treated CD indi-
viduals in the Fernandez study supported this approach
[14]. However, a previous study by the same group
showed methylation differences in the promoter of NFκB
was less pronounced in GFD-treated CD and controls,
compared to methylation differences between individuals
with active CD and controls [38]. Epigenetic profiles can
change over time and during disease progression [39]. It is
possible that the use of longer term GFD-treated individ-
uals and saliva instead of duodenal tissues could explain
the absence of large methylation differences. Longitudinal
studies comparing DNA methylation profiles at diagnosis
and then following treatment on a GFD with healthy con-
trols could help to differentiate DNA methylation changes
that are disease state specific.
In this study probes targeting non-CpG sites were re-
moved prior to analyses. In humans non-CpG methylation
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was traditionally thought to be limited to embryonic stem
cells, however recent evidence has shown that it accounts
for 35% of total DNA methylation in the adult brain, and
is functionally active with methylation and demethylation
of these sites linked to transcriptional regulation of genes
with promoters characterized by a low-density of CpG
sites [40]. Further investigation into methylation levels at
non-CpG sites is warranted to determine whether non-
CpG methylation has a role in CD.
Conclusion
Our study identified a differentially methylated region
near the SLC17A3 gene that may be associated with CD,
however that remains to be validated. Further work in
individuals newly diagnosed with CD, as well as in intes-
tinal and saliva samples of individuals with CD is needed
to determine whether unique DNA methylation patterns
are associated with CD and to conform to previously
published studies.
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